Literature DB >> 16359234

Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.

Maria Malm1, Erik Rollman, Mart Ustav, Jorma Hinkula, Kai Krohn, Britta Wahren, Vesna Blazevic.   

Abstract

The correlate of protection in human immunodeficiency virus (HIV) infection is not known, but preclinical and clinical studies support the involvement of both antibodies and cellular immunity. In addition, the existence of multiple HIV clades makes HIV vaccine design especially challenging. We have constructed a vaccine platform with an HIV-1 subtype B DNA immunogen expressing full length consensus sequences from HIV-1 rev, nef, tat, and gag with additional cellular epitope clusters from the env and pol regions. Furthermore, this platform has been extended to three additional plasmids expressing the same immunogens but originating from subtypes A or C consensus or FGH ancestral sequences. Immunogenicity in BALB/c mice, by gene gun or intramuscular delivery, revealed strong IFN-gamma production in response to in vitro re-stimulation with a H-2d restricted gag peptide (AMQMLKETI) or even stronger toward an env epitope (RGPGRAFVTI). Weak humoral immunity was detected. Gene gun immunization with a cocktail of all four plasmids induced pre-challenge cellular immunity in C57Bl6/A2.01 mice and subsequently a robust frequency of protection (11/12 animals) after experimental challenge with subtype A or B HIV-1/Murine Leukemia Virus (HIV-1/MuLV). The cross-clade protection observed in this challenge experiment demonstrates that these multigene/multiepitope HIV DNA immunogens are likely to be potent immunogens also against the HIV-infection of human beings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359234     DOI: 10.1089/vim.2005.18.678

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  9 in total

Review 1.  Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Authors:  Flavia Ferrantelli; Stefano Buttò; Aurelio Cafaro; Britta Wahren; Barbara Ensoli
Journal:  Springer Semin Immunopathol       Date:  2006-09-16

2.  Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Authors:  Dominick J Laddy; Jian Yan; Natasha Corbitt; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

3.  Identification of immunodominant B- and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of Leptospira interrogans.

Authors:  Xu'ai Lin; Jinfang Zhao; Jing Qian; Yafei Mao; Jianping Pan; Liwei Li; Huiqin Peng; Yihui Luo; Jie Yan
Journal:  Clin Vaccine Immunol       Date:  2010-03-17

4.  A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

Authors:  Brendan M Giles; Ted M Ross
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

Review 5.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

Review 6.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

7.  Characterization of conserved combined T and B cell epitopes in Leptospira interrogans major outer membrane proteins OmpL1 and LipL41.

Authors:  Xu'ai Lin; Aihua Sun; Ping Ruan; Zhe Zhang; Jie Yan
Journal:  BMC Microbiol       Date:  2011-01-26       Impact factor: 3.605

8.  Dissecting the dynamics of HIV-1 protein sequence diversity.

Authors:  Yongli Hu; Paul ThiamJoo Tan; Tin Wee Tan; J Thomas August; Asif M Khan
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

9.  Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

Authors:  Dominick J Laddy; Jian Yan; Michele Kutzler; Darwyn Kobasa; Gary P Kobinger; Amir S Khan; Jack Greenhouse; Niranjan Y Sardesai; Ruxandra Draghia-Akli; David B Weiner
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.